Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • KevonLooney@lemm.ee
    link
    fedilink
    arrow-up
    27
    arrow-down
    2
    ·
    11 months ago

    It does work, amazingly. I had Covid a few times and took Paxlovid the last time. It works better than any drug I’ve taken. After taking the first dose, there were no more Covid symptoms within 4-6 hours.

    The problem with Paxlovid (besides the cost) is that it gives you a new set of side effects: weird joint and muscle pain, a metallic taste in the mouth, etc. They’re better than Covid though. And it won’t kill you.

    • thepianistfroggollum@lemmynsfw.com
      link
      fedilink
      English
      arrow-up
      2
      arrow-down
      16
      ·
      11 months ago

      Just because it worked for you doesn’t mean that the effectiveness in their trials represents real world numbers. I’m not pulling this out of my ass, I was told this by a medical professional.

      • KevonLooney@lemm.ee
        link
        fedilink
        arrow-up
        13
        arrow-down
        2
        ·
        11 months ago

        There are many types of “medical professionals”. Only a vast minority actually read and interpret trial data.

        I’m going to trust my direct experience with the drug (I know it works) and real world studies like below.

        Conclusions: This study suggests that in the era of Omicron and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.

        https://pubmed.ncbi.nlm.nih.gov/35653428/

        • SoleInvictus@lemmy.world
          link
          fedilink
          arrow-up
          8
          arrow-down
          4
          ·
          11 months ago

          Excuse me, that study only examined 140,219 patients. You’ll need WAY more, at least one million, to argue against the anecdotal opinion of a random, unspecified ‘medical professional’.

          /s so hard

          • thepianistfroggollum@lemmynsfw.com
            link
            fedilink
            English
            arrow-up
            2
            arrow-down
            3
            ·
            11 months ago

            Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.

            Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.

        • FontMasterFlex@lemmy.world
          link
          fedilink
          arrow-up
          3
          arrow-down
          3
          ·
          11 months ago

          dude’s not saying it doesn’t work. he’s saying it doesn’t work as well as advertised. that perhaps doesn’t mean it’s only 50% effective for 100% people. perhaps it’s 100% effective for 20% of people. Think dude.

          • Jax@sh.itjust.works
            link
            fedilink
            arrow-up
            3
            arrow-down
            1
            ·
            edit-2
            11 months ago

            Yeah I’m gonna go ahead and say the guy throwing out accusations like false advertising is the one that needs to think a little more.

            Paxlovid has only ever been advertised as something that “can reduce the risk of hospitalization and death by around 89%”.

            The idea that, somehow, all of the people associated with coming to the “89%” number are somehow magically also associated with a subset of the population that responds well to it is fucking nonsense. It’s the exact same garbage logic that conspiracy theorists use.

        • thepianistfroggollum@lemmynsfw.com
          link
          fedilink
          English
          arrow-up
          1
          arrow-down
          3
          ·
          11 months ago

          Ah, that was the era of omicron. We’re over 21 months and several variants past that now, and I was given the information about paxlovid last week.

          Also, that study only covers a single month in Israel in 2022 and only 2.6% of the sample was given paxlovid.